Monday’s analyst upgrades and downgrades

Analyst updates were broadly constructive, led by Aritzia, where Stifel raised its target to $158 from $150 and lifted Q4FY26 EPS to $1.07, 5 cents above consensus, while expecting FY27 revenue growth of 15%-19%. Aclara Resources was upgraded to outperform and its target doubled to $6 from $3 on stronger rare earth economics and strategic validation, while several other names saw target/ratings changes tied to AI exposure, commodities, and sector positioning. The report is primarily analyst-driven and should influence individual stocks more than the broader market.

Analysis

The common thread is not “better earnings” but a widening dispersion regime: AI is creating a valuation hierarchy where names with proprietary workflows, installed bases, or direct monetization of infrastructure scarcity are likely to hold multiples even if growth slows. That favors SHOP, KXS.TO, VHI.TO, GIB, and BAM over the next 2-4 quarters, while CVO.TO, CMG.TO, and WPRT look exposed to the market’s willingness to pay for software or self-help stories without a clear defensibility premium. The second-order effect is that software peers tied to customer acquisition or search/discovery are at the highest risk of multiple compression, even if fundamentals remain “fine” in the near term.

Aritzia is the cleanest near-term momentum trade in the tape. The key is not just traffic or comps, but cash conversion: if operating leverage plus inventory discipline holds, the company can fund buybacks and growth capex simultaneously, which creates a self-reinforcing EPS bridge into the next two fiscal years. That said, expectations are now elevated enough that the stock becomes a guidance-management story; any normalization in U.S. growth or margins likely hits the multiple first, with earnings revisions following later.

Aclara is the most underappreciated geopolitical optionality name in the basket. The market is still treating it like a development-stage rare earth story, but the real asset is strategic scarcity: Western buyers increasingly need non-China supply chains, and that can produce price floors, offtakes, and financing support that materially de-risk project economics. The upside is not linear; if HREE pricing remains bifurcated and a credible offtake package emerges, the stock can rerate far above current fair value estimates. The main risk is timing — approvals and construction milestones are years away, so the trade only works if investors pay for policy optionality before cash flow visibility arrives.

Key Decisions for Investors

• Long SHOP / short a basket of CVO.TO + CMG.TO on a 3-6 month horizon: own the AI-resilient, platform-based compounder while fading names where monetization is more exposed to search/discovery disruption; target 15-20% relative outperformance with limited beta if software multiples stay bifurcated.
• Buy ATZ.TO on any post-earnings pullback or weak guidance scare over the next 1-2 weeks; risk/reward remains positive into FY27 revisions, but trim if the stock trades above a 30x forward multiple and same-store sales decelerate sequentially.
• Initiate a tactical long in USARW / ARA-T (Aclara) for 6-12 months as a geopolitics optionality trade; upside is a re-rate on offtake/financing headlines, but size small because execution is years out and dilution risk remains high.
• Add KXS.TO and VHI.TO on weakness for a 2-4 quarter horizon; both screen as higher-quality AI beneficiaries with less disruption risk than the average Canadian software name, and should outperform if the market keeps rewarding defensible workflow software.
• Hold/overweight BAM ahead of fund close catalysts into the next quarter; this is a lower-beta way to express AI infrastructure spend without owning software multiple risk, with a better downside profile if sentiment around alt managers stays cautious.